Rosales-Alexander José Luis, Balsalobre Aznar Jerónimo, Magro-Checa César
Rheumatology Department, Hospiten Ramblas, Santa Cruz de Tenerife.
Rheumatology Department, San Cecilio University Hospital, Granada, Spain.
Open Access Rheumatol. 2014 May 8;6:39-47. doi: 10.2147/OARRR.S39039. eCollection 2014.
Calcium pyrophosphate dihydrate crystal deposition disease (CPPD) is an inflammatory arthritis produced by the deposition of calcium pyrophosphate (CPP) crystals in the synovium and periarticular soft tissues. It is the third most common inflammatory arthritis. Diagnosis is suspected on the basis of the clinical picture and radiographic/laboratory findings. The reference standard for the diagnosis of CPPD is based on the identification of CPP crystals in synovial fluid by light microscopy, compensated polarized light microscopy, or phase contrast microscopy. Most treatment approaches for CPPD are based upon clinical experience and not upon controlled trials. They range - depending on the subtype and the characteristics of symptoms - from no treatment to interleukin-1 blockade antibodies or specific therapy for an underlying disease. This review summarizes all we know so far about the diagnosis and management of CPPD.
焦磷酸钙二水合物晶体沉积病（CPPD）是一种由焦磷酸（CPP）晶体沉积于滑膜和关节周围软组织而引起的炎性关节炎。它是第三常见的炎性关节炎。根据临床表现及影像学/实验室检查结果怀疑诊断。CPPD诊断的参考标准基于通过光学显微镜、补偿偏振光显微镜或相差显微镜在滑液中鉴定CPP晶体。CPPD的大多数治疗方法基于临床经验而非对照试验。根据亚型和症状特点，治疗方法从无需治疗到使用白细胞介素-1阻断抗体或针对基础疾病的特异性治疗不等。本综述总结了目前我们对焦磷酸钙二水合物晶体沉积病的诊断和管理的所有了解。
